Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Sales (2017 - 2025)

UroGen Pharma's Return on Sales history spans 9 years, with the latest figure at 0.7% for Q4 2025.

  • For Q4 2025, Return on Sales rose 83.0% year-over-year to 0.7%; the TTM value through Dec 2025 reached 1.4%, up 1.0%, while the annual FY2025 figure was 1.4%, 1.0% up from the prior year.
  • Return on Sales reached 0.7% in Q4 2025 per URGN's latest filing, up from 1.21% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.7% in Q4 2025 to a low of 3.46% in Q1 2021.
  • Average Return on Sales over 5 years is 1.69%, with a median of 1.61% recorded in 2022.
  • Peak YoY movement for Return on Sales: soared 978537bps in 2021, then tumbled -53bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 1.76% in 2021, then rose by 9bps to 1.6% in 2022, then surged by 31bps to 1.11% in 2023, then tumbled by -38bps to 1.53% in 2024, then soared by 54bps to 0.7% in 2025.
  • Per Business Quant, the three most recent readings for URGN's Return on Sales are 0.7% (Q4 2025), 1.21% (Q3 2025), and 2.06% (Q2 2025).